Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers

NCT04761744 is registered in ClinicalTrials.gov with Korean Cancer Study Group as lead sponsor.

NCT NCT04761744
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04761744 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers
Lead sponsor
Korean Cancer Study Group
Phase
Phase 2
Overall status
Unknown status
Start date
June 14, 2019
Completion date
December 31, 2021
Enrollment
48 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ddr gene mutation, metastatic solid tumor